STX-478   Click here for help

GtoPdb Ligand ID: 12903

Synonyms: STX478
PDB Ligand
Compound class: Synthetic organic
Comment: STX-478 (formerly ST-814; Scorpion Therapeutics) is an oral, CNS-penetrant PI3Kα allosteric inhibitor, that is intended for treatment of cancers with oncogenic PI3Kα mutations (e.g. H1047X substitutions).
The chemical structure shown here was revealed during the First Time Disclosures session at the ACS meeting in September 2023, and we picked it up from Drug Hunter. The discovery of STX-478 (including its structure) was formally disclosed in a Cancer Discovery article by Buckbinder et al. (2023) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 101.1
Molecular weight 401.29
XLogP 0.73
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=C([C@H](C(F)(F)F)NC(=O)NC2=CN=C(N)N=C2)OC3=C1C=C(C=C3F)F
Isomeric SMILES CC1=C(OC2=C1C=C(F)C=C2F)[C@@H](NC(=O)NC3=CN=C(N)N=C3)C(F)(F)F
InChI InChI=1S/C16H12F5N5O2/c1-6-9-2-7(17)3-10(18)12(9)28-11(6)13(16(19,20)21)26-15(27)25-8-4-23-14(22)24-5-8/h2-5,13H,1H3,(H2,22,23,24)(H2,25,26,27)/t13-/m1/s1
InChI Key LGPNQALKGDDVBD-CYBMUJFWSA-N
Bioactivity Comments
Additional PI3Kα inhibitors are claimed in Scorpion Therapeutics' 2023 patent WO2023018636A1 [2].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha Hs Inhibitor Inhibition 7.2 – 8.3 pKd - 1
pKd 8.3 (Kd 4.7x10-9 M) [1]
Description: Affinity for PI3Kα with the H1047R mutation
pKd 7.2 (Kd 7x10-8 M) [1]
Description: Affinity for wild type PI3Kα